Cancers · Nov 16, 2026
Insertional Mutagenesis in Hematopoietic Stem-Cell-Based Gene Therapy Trials Using Lentiviral Vectors
By Staal FJT, Leemans C, Pike-Overzet K
Lentiviral vectors enable durable gene correction in hematopoietic stem cells but carry a risk of insertional mutagenesis, potentially leading to clonal expansion and hematologic malignancies. This review examines the mechanisms underlying this risk, recent clinical safety signals, and strategies to improve the safety of gene therapy. Here, we review evidence from clinical trials, mechanistic studies, and preclinical research, focusing on vector integration, promoter activity, clonal hematopoiesis, and treatment-related factors influencing leukemogenesis. Insertional mutagenesis can alter gene expression through enhancer-mediated activation, aberrant transcript formation, and disruption of endogenous regulatory elements. Recent cases of myelodysplastic syndrome and acute leukemia following gene therapy for cerebral adrenoleukodystrophy have highlighted the potential genotoxicity of strong internal promoters, particularly MND. However, outcomes in adenosine deaminase-deficient severe combined immunodeficiency suggest that oncogenic risk is context-dependent. Disease biology, patient age, pre-existing somatic mutations, vector copy number, conditioning regimens, and post-transplant clonal selection may interact to influence malignancy development. In conclusion, insertional mutagenesis remains a clinically relevant challenge despite advances in lentiviral vector design. Integration site analysis and emerging statistical tools, including MELISSA, may facilitate earlier detection of potentially hazardous clonal expansion. Improving safety requires optimized promoter selection, reduced vector copy numbers, enhanced preclinical assessment, individualized risk stratification, and comprehensive long-term surveillance that integrates vector insertion and somatic mutation analyses.